Disposition and metabolism of a novel prostanoid antiglaucoma medication, tafluprost, following ocular administration to rats

Fukano Y., Kawazu K.

2009
Drug Metabolism and Disposition

View publication

Therapeutic Area

Glaucoma
Technology

Pharmacology
Categories

Preclinical development

Affiliations

Non-clinical Research Group, Research and Development Center, Santen Pharmaceutical Co., Ltd., 8916-16, Takayama-cho, Ikoma-shi, 630-0101, Nara, Japan

Related Publications

The Antiglaucoma Agent and EP2 Receptor Agonist Omidenepag Does Not Affect Eyelash Growth in Mice

Esaki Y., Katsuta O., Kamio H., Noto T., Mano H., Iwamura R., Yoneda K., Odani-Kawabata N., Morishima K., Shams N.K.

In vitro and in vivo evaluation of a preservative-free cationic emulsion of latanoprost in corneal wound healing models

Liang H., Baudouin C., Daull P., Garrigue J.-S., Buggage R., Brignole-Baudouin F.

A comparative study of a preservative-free latanoprost cationic emulsion (catioprost) and a BAK-preserved latanoprost solution in animal models

Daull P., Buggage R., Lambert G., Faure M.-O., Serle J., Wang R.-F., Garrigue J.-S.

View all Glaucoma publications

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022